IASLC World Conference on Lung Cancer

When compared with osimertinib, amivantamab plus lazertinib showed a trend toward favorable overall survival in patients with EGFR-mutant advanced NSCLC.

An exploratory analysis from the TROPION-Lung 01 study shows that positivity for TROP2 normalized membrane ratio can be predictive for improved efficacy in patients with non–small cell lung cancer treated with datopotamab deruxtecan.

Triparna Sen, PhD, discusses findings from an interim analysis of the phase 2 IDeate-Lung01 trial in patients with extensive-stage small cell lung cancer.

Event-free survival improved with perioperative nivolumab vs neoadjuvant nivolumab plus chemotherapy in resectable NSCLC, according to a comparison of 2 trials.

Several novel combinations yielded high pCR and mPR rates in patients with resectable non–small cell lung cancer, according to data from the 2024 IASLC conference.

Ivonescimab produced a significant improvement in PFS vs pembrolizumab as frontline therapy in patients with PD-L1–positive advanced NSCLC.

Alexander I. Spira MD, PhD, FACP, FASCO, discusses updated findings from the phase 3 MARIPOSA study in EGFR-mutated locally advanced or metastatic NSCLC.

Global surveys from 2018 and 2024 demonstrated barriers to optimizing biomarker testing for patients with early- or late-stage lung cancer.

A 12-mg/kg dose of ifinatamab deruxtecan improved efficacy compared with an 8-mg/kg dose in heavily pretreated patients with extensive-stage small cell lung cancer.

Ticiana Leal, MD, discusses the rationale for and findings from a PD-L1 subgroup analysis of the phase 3 LUNAR trial in patients with metastatic non–small cell lung cancer.

The addition of atezolizumab to bevacizumab, carboplatin, and pemetrexed or paclitaxel (ABCP) did not result in a statistically significant improvement in progression-free survival vs BCP for patients with metastatic nonsquamous non–small cell lung cancer in the first line, missing the primary end point of the phase 3 IMpower151 study.

Marcelo Vailati Negrao, MD, discusses efficacy findings from the phase 1b/2 KontRASt-01 trial (NCT04699188) in patients with KRAS G12C–mutated solid tumors.

Shirish M. Gadgeel, MD, discusses 2-year follow-up data from the phase 1/2 KRYSTAL-1 trial in patients with advanced or metastatic non–small cell lung cancer harboring KRAS G12C mutations.

Treatment with durvalumab plus tremelimumab and chemotherapy led to higher rates of long-term clinical benefit compared with chemotherapy alone in the treatment of patients with first-line metastatic non–small cell lung cancer.

The addition of perioperative durvalumab to neoadjuvant chemotherapy led to a significant improvement in terms of pathological complete response and event-free survival compared with placebo plus chemotherapy in patients with resectable non–small cell lung cancer.

The addition of durvalumab to chemotherapy prior to surgery, followed by adjuvant durvalumab, did not provide a clear clinical benefit in patients with early-stage non–small cell lung cancer harboring an EGFR mutation, according to data from the phase 3 AEGEAN trial.

Zongertinib will proceed to phase 1b evaluation at doses of 120 mg and 240 mg once daily in patients with HER2–mutant non–small cell lung cancer following preliminary efficacy signals and acceptable safety in patients with advanced HER2–mutant solid tumors enrolled in the dose-escalation portion of the phase 1a/b BEAMION Lung-1 trial.

Treatment with durvalumab was associated with lower real-world progression-free survival in patients with unresectable, stage III EGFR-mutated non–small cell lung cancer vs patients with EGFR wild-type disease.

Osimertinib in combination with platinum-based therapy and pemetrexed demonstrated a statistically significant and clinically meaningful improvement in progression-free survival vs osimertinib monotherapy in patients with EGFR-mutated advanced non–small cell lung cancer.

The addition of datopotamab deruxtecan to durvalumab, with or without carboplatin, demonstrated favorable efficacy and safety in patients with advanced or metastatic non–small cell lung cancer, according to an interim analysis of the phase 1b TROPION-Lung04 trial.

David Harpole, MD, discusses findings from an exploratory analysis of the phase 3 AEGEAN trial in patients with EGFR-mutated non–small cell lung cancer.

Pasi A. Jänne, MD, PhD, discusses findings from the phase 3 FLAURA2 trial in patients with EGFR-mutant non–small cell lung cancer.

The combination of the SHP2 inhibitor TNO155 and the KRAS G12C inhibitor JDQ433 showed antitumor activity in patients with KRAS G12C-mutated solid tumors, including non–small cell lung cancer, irrespective of prior treatment with a KRAS G12C inhibitor.

Treatment with at least 90 μg/kg of the novel DLLC-targeting T-cell–engager BI 764532 was well tolerated and led to tumor shrinkage in patients with small cell lung cancer and neuroendocrine carcinoma.

Treatment with iruplinalkib significantly improved progression-free survival and produced a higher objective response rate compared with crizotinib in patients with ALK TKI–naïve, locally advanced and metastatic ALK-positive non–small cell lung cancer, according to data from a prespecified interim analysis of the phase 3 INSPIRE trial.

Treatment with the antibody-drug conjugate ifinatamab deruxtecan in heavily pretreated patients with small cell lung cancer led to promising efficacy and a manageable safety profile.

The use of the oral, brain penetrant, furmonertinib, resulted in encouraging responses and a tolerable safety profile in patients with advanced non–small cell lung cancer harboring EGFR exon 20 insertion mutations, according to data from the phase 1b FAVOUR trial.

Early antitumor activity has been observed in patients with metastatic non–small cell lung cancer treated with the combination of sacituzumab govitecan-hziy and pembrolizumab in the first-line setting.